Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 7
2012 6
2013 11
2014 17
2015 16
2016 16
2017 15
2018 8
2019 12
2020 16
2021 15
2022 19
2023 13
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Results by year

Citations

8 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer.
Fournel L, Wu Z, Stadler N, Damotte D, Lococo F, Boulle G, Ségal-Bendirdjian E, Bobbio A, Icard P, Trédaniel J, Alifano M, Forgez P. Fournel L, et al. Among authors: lococo f. Cancer Lett. 2019 Nov 1;464:5-14. doi: 10.1016/j.canlet.2019.08.005. Epub 2019 Aug 9. Cancer Lett. 2019. PMID: 31404614
The number of clinical protocols testing combined therapies including immune check-point inhibitors and platinum salts is currently increasing in lung cancer treatment, however preclinical studies and rationale are often lacking. ...We also confirmed the up-regulati …
The number of clinical protocols testing combined therapies including immune check-point inhibitors and platinum salts is currently increasi …
Target Therapy in Lung Cancer.
Cafarotti S, Lococo F, Froesh P, Zappa F, Andrè D. Cafarotti S, et al. Among authors: lococo f. Adv Exp Med Biol. 2016;893:127-136. doi: 10.1007/978-3-319-24223-1_6. Adv Exp Med Biol. 2016. PMID: 26667341 Review.
Because these variants have differing genetic and biological properties correct classification of lung cancer is necessary to assure that lung cancer patients receive optimum management. ...Is now the beginning of personalized therapy era that is ideal …
Because these variants have differing genetic and biological properties correct classification of lung cancer is necessary to …
BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3.
Reggiani F, Talarico G, Gobbi G, Sauta E, Torricelli F, Manicardi V, Zanetti E, Orecchioni S, Falvo P, Piana S, Lococo F, Paci M, Bertolini F, Ciarrocchi A, Sancisi V. Reggiani F, et al. Among authors: lococo f. Nat Commun. 2024 Mar 22;15(1):2567. doi: 10.1038/s41467-024-46778-8. Nat Commun. 2024. PMID: 38519469 Free PMC article.
Non-small-cell lung carcinoma (NSCLC) is the most common lung cancer and one of the pioneer tumors in which immunotherapy has radically changed patients' outcomes. ...
Non-small-cell lung carcinoma (NSCLC) is the most common lung cancer and one of the pioneer tumors in which immunothera …
Pathological and clinical features of multiple cancers and lung adenocarcinoma: a multicentre study.
Bertoglio P, Ventura L, Aprile V, Cattoni MA, Nachira D, Lococo F, Rodriguez Perez M, Guerrera F, Minervini F, Gnetti L, Lenzini A, Franzi F, Querzoli G, Rindi G, Bellafiore S, Femia F, Bogina GS, Bacchin D, Kestenholz P, Ruffini E, Paci M, Margaritora S, Imperatori AS, Lucchi M, Ampollini L, Terzi AC. Bertoglio P, et al. Among authors: lococo f. Interact Cardiovasc Thorac Surg. 2022 Jun 15;35(1):ivac047. doi: 10.1093/icvts/ivac047. Interact Cardiovasc Thorac Surg. 2022. PMID: 35188192 Free PMC article.
OBJECTIVES: Lung cancer is increasingly diagnosed as a second cancer. Our goal was to analyse the characteristics and outcomes of early-stage resected lung adenocarcinomas in patients with previous cancers (PC) and correlations with adenocarcinoma subt …
OBJECTIVES: Lung cancer is increasingly diagnosed as a second cancer. Our goal was to analyse the characteristics and o …
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study.
Lococo F, Boldrini L, Diepriye CD, Evangelista J, Nero C, Flamini S, Minucci A, De Paolis E, Vita E, Cesario A, Annunziata S, Calcagni ML, Chiappetta M, Cancellieri A, Larici AR, Cicchetti G, Troost EGC, Ádány R, Farré N, Öztürk E, Van Doorne D, Leoncini F, Urbani A, Trisolini R, Bria E, Giordano A, Rindi G, Sala E, Tortora G, Valentini V, Boccia S, Margaritora S, Scambia G. Lococo F, et al. BMC Cancer. 2023 Jun 13;23(1):540. doi: 10.1186/s12885-023-10997-x. BMC Cancer. 2023. PMID: 37312079 Free PMC article.
BACKGROUND: The current management of lung cancer patients has reached a high level of complexity. Indeed, besides the traditional clinical variables (e.g., age, sex, TNM stage), new omics data have recently been introduced in clinical practice, thereby making more …
BACKGROUND: The current management of lung cancer patients has reached a high level of complexity. Indeed, besides the traditi …
Classification of different patterns of pulmonary adenocarcinomas.
Truini A, Santos Pereira P, Cavazza A, Spagnolo P, Nosseir S, Longo L, Jukna A, Lococo F, Vincenzi G, Bogina G, Tiseo M, Rossi G. Truini A, et al. Among authors: lococo f. Expert Rev Respir Med. 2015 Oct;9(5):571-86. doi: 10.1586/17476348.2015.1083428. Epub 2015 Aug 27. Expert Rev Respir Med. 2015. PMID: 26313326 Review.
The epidemic increase of adenocarcinoma histology accounting for more than 50% of primary lung malignancies and the advent of effective molecular targeted-therapies against specific gene alterations characterizing this tumor type have led to the reconsideration of the path …
The epidemic increase of adenocarcinoma histology accounting for more than 50% of primary lung malignancies and the advent of effecti …
Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos.
Maisonneuve P, Rampinelli C, Bertolotti R, Misotti A, Lococo F, Casiraghi M, Spaggiari L, Bellomi M, Novellis P, Solinas M, Dieci E, Alloisio M, Fontana L, Persechino B, Iavicoli S, Veronesi G. Maisonneuve P, et al. Among authors: lococo f. Lung Cancer. 2019 May;131:23-30. doi: 10.1016/j.lungcan.2019.03.003. Epub 2019 Mar 6. Lung Cancer. 2019. PMID: 31027694 Review.
OBJECTIVES: Smoking is the main risk factor for lung cancer, but environmental and occupational exposure to carcinogens also increase lung cancer risk. ...CONCLUSION: Persons occupationally exposed to asbestos should be monitored to gather more informa …
OBJECTIVES: Smoking is the main risk factor for lung cancer, but environmental and occupational exposure to carcinogens also i …
Role of Peripheral Blood Markers for Detecting Response and Predicting Prognosis in Patients with Non-small-cell Lung Cancer Undergoing Neoadjuvant Therapy and Surgery.
Lococo F, Chiappetta M, Evangelista J, Sperduti I, Nachira D, Porziella V, Congedo MT, Bria E, Vita E, Cesario A, Sassorossi C, Charles-Davies D, Boldrini L, Massaccesi M, Valentini V, Margaritora S. Lococo F, et al. Lung. 2022 Jun;200(3):393-400. doi: 10.1007/s00408-022-00541-2. Epub 2022 Jun 2. Lung. 2022. PMID: 35652971
INTRODUCTION: To date, no validated predictors of response before neoadjuvant therapy (NAD) are currently available in locally advanced non-small-cell lung cancer (NSCLC). In this study, different peripheral blood markers were investigated before NAD (pre-NAD) and a …
INTRODUCTION: To date, no validated predictors of response before neoadjuvant therapy (NAD) are currently available in locally advanced non- …
152 results